Embecta Corp. (FRA:JX7)

Germany flag Germany · Delayed Price · Currency is EUR
2.582
+0.145 (5.95%)
Last updated: May 21, 2026, 3:25 PM CET
Market Cap156.11M -75.0%
Revenue (ttm)904.16M -3.4%
Net Income97.05M +111.9%
EPS1.63 +111.2%
Shares Outn/a
PE Ratio1.61
Forward PE2.13
Dividend0.52 (20.05%)
Ex-Dividend DateFeb 27, 2026
Volumen/a
Average Volume191
Open2.586
Previous Close2.437
Day's Range2.578 - 2.591
52-Week Range2.437 - 12.900
Betan/a
RSI17.03
Earnings DateMay 5, 2026

About Embecta

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1924
Employees 1,850
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol JX7

Financial Performance

In fiscal year 2025, Embecta's revenue was $1.08 billion, a decrease of -3.80% compared to the previous year's $1.12 billion. Earnings were $95.40 million, an increase of 21.84%.

Financial numbers in USD Financial Statements

News

Embecta price target lowered to $3 from $11 at BofA

BofA analyst Travis Steed lowered the firm’s price target on Embecta (EMBC) to $3 from $11 and keeps an Underperform rating on the shares. After having hosted 34 medtech companies…

3 days ago - TheFly

Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification

Embecta NASDAQ: EMBC President and CEO Devdatt Kurdikar said the company's recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-relate...

5 days ago - MarketBeat

embecta Completes Acquisition of Owen Mumford Holdings Limited

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced...

6 days ago - GlobeNewsWire

Embecta Transcript: Bank of America Global Healthcare Conference 2026

U.S. instability from share loss and market softness prompted a guidance cut and accelerated diversification efforts. New products, B2B partnerships, and the Owen Mumford acquisition are expected to drive growth and broaden the portfolio. Free cash flow remains strong, supporting buybacks and debt reduction.

7 days ago - Transcripts

embecta to Participate at the 2026 BofA Securities Global Health Care Conference

PARSIPPANY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the 2026 BofA Securities Global Health Care Conference in Las ...

13 days ago - GlobeNewsWire

Embecta price target lowered to $5 from $12 at Mizuho

Mizuho lowered the firm’s price target on Embecta (EMBC) to $5 from $12 and keeps a Neutral rating on the shares.

14 days ago - TheFly

Embecta Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Embecta Corp. (NASDAQ: EMBC). The investigation focuses on Embecta's execut...

15 days ago - GlobeNewsWire

Embecta Earnings Call Transcript: Q2 2026

Q2 2026 saw a 14.4% revenue decline year-over-year, driven by U.S. pen needle share loss and market softness, prompting a downward revision of full-year guidance. The Owen Mumford acquisition is set to diversify the portfolio and contribute $30 million to revenue.

16 days ago - Transcripts

Embecta Earnings release: Q2 2026

Embecta released its Q2 2026 earnings on May 5, 2026, summarizing the period's financial results.

16 days ago - Filings

Embecta Slides: Q2 2026

Embecta has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 5, 2026.

16 days ago - Filings

Embecta Quarterly report: Q2 2026

Embecta has published its Q2 2026 quarterly earnings report on May 5, 2026.

16 days ago - Filings

Embecta lowers FY26 adjusted EPS view to $1.55-$1.75 from $2.80-$3.00

Lowers FY26 revenue view to $1.015B-$1.035B from $1.071B-$1.093B. Consensus is for FY26 EPS $2.82 and for revenue $1.07B.

16 days ago - TheFly

Embecta reports Q2 adjusted EPS 27c, consensus 42c

Reports Q2 revenue $22.18M, consensus $235.66M. “We were disappointed with our second quarter results as they were significantly below our expectations, driven by a combination of factors which impact...

16 days ago - TheFly

embecta Announces Quarterly Cash Dividend

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding sh...

16 days ago - GlobeNewsWire

Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical ...

16 days ago - GlobeNewsWire

Embecta management to meet virtually with BTIG

Virtual Meeting to be held on May 6 hosted by BTIG.

21 days ago - TheFly

embecta to Report Fiscal Second Quarter Financial Results

PARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medica...

4 weeks ago - GlobeNewsWire

Embecta price target lowered to $12 from $14 at Mizuho

Mizuho lowered the firm’s price target on Embecta (EMBC) to $12 from $14 and keeps a Neutral rating on the shares. The firm lowered estimates and price targets for several…

5 weeks ago - TheFly

Embecta price target lowered to $22 from $25 at BTIG

BTIG lowered the firm’s price target on Embecta (EMBC) to $22 from $25 and keeps a Buy rating on the shares as part of a broader research name on Medical…

5 weeks ago - TheFly

Embecta acquiring Owen Mumford Holdings

Embecta (EMBC) has entered into a definitive agreement to acquire Owen Mumford Holdings, a privately held, UK-based manufacturer of medical devices and drug-delivery technologies, in a transaction val...

2 months ago - TheFly

embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited

Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based med...

2 months ago - GlobeNewsWire

Embecta elects CEO Devdatt Kurdikar as chairman

Embecta (EMBC) announced that the board of directors of Embecta has elected Devdatt Kurdikar as chairman of the board and Claire Pomeroy as lead independent director, effective immediately. These chan...

3 months ago - TheFly

embecta names new Chairman of the Board and Lead Independent Director

PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...

3 months ago - GlobeNewsWire

Embecta Earnings Call Transcript: Q1 2026

Q1 2026 revenue was $261M, down slightly year-over-year, with U.S. declines offset by strong international growth. Guidance for FY2026 is reaffirmed but expected near the lower end due to U.S. pricing headwinds, while international performance and GLP-1 opportunities remain strong.

3 months ago - Transcripts

Embecta Quarterly report: Q1 2026

Embecta has published its Q1 2026 quarterly earnings report on February 5, 2026.

3 months ago - Filings